Εμφάνιση απλής εγγραφής

dc.creatorMalizos K., Sarma J., Seaton R.A., Militz M., Menichetti F., Riccio G., Gaudias J., Trostmann U., Pathan R., Hamed K.en
dc.date.accessioned2023-01-31T08:56:19Z
dc.date.available2023-01-31T08:56:19Z
dc.date.issued2016
dc.identifier10.1007/s10096-015-2515-6
dc.identifier.issn09349723
dc.identifier.urihttp://hdl.handle.net/11615/76197
dc.description.abstractOsteomyelitis is a serious infection predominantly caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Orthopaedic device-related infections are complex and require a careful combination of surgical intervention and antimicrobial therapy. Daptomycin, a cyclic lipopeptide, effectively penetrates soft tissue and bone and demonstrates rapid concentration-dependent bactericidal activity against Gram-positive pathogens. This retrospective, non-interventional study evaluated clinical outcomes in patients with osteomyelitis or orthopaedic device infections treated with daptomycin from the European Cubicin® Outcomes Registry and Experience (EU-CORESM) study. Patients were treated between January 2006 and April 2012, with follow-up to 2014. Clinical outcomes were assessed as success (cured or improved), failure or non-evaluable. Of 6,075 patients enrolled, 638 (median age, 63.5 years) had primary infections of osteomyelitis or orthopaedic device infections, 224 had non-prosthetic osteomyelitis, 208 had osteomyelitis related to a permanent or temporary prosthetic device, and 206 had orthopaedic device infections. The most commonly isolated pathogen was S. aureus (214 [49.1 %]; 24.8 % were MRSA). Overall, 455 (71.3 %) patients had received previous antibiotic therapy. Patients underwent surgical interventions, including tissue (225 [35.3 %]) and bone (196 [30.7 %]) debridement, as part of their treatment. Clinical success rates were 82.7 % and 81.7 % in S. aureus and coagulase-negative staphylococcal infections. Adverse events (AEs) and serious AEs assessed as possibly related to daptomycin were observed in 6.7 % and 1.9 % of patients, respectively. Daptomycin was discontinued by 5.5 % of patients due to AEs and 10 (1.6 %) deaths were reported. In conclusion, daptomycin was effective and safe in patients with osteomyelitis or orthopaedic device infections. © 2015, The Author(s).en
dc.language.isoenen
dc.sourceEuropean Journal of Clinical Microbiology and Infectious Diseasesen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84954390629&doi=10.1007%2fs10096-015-2515-6&partnerID=40&md5=e95c7dba3c859a980c97c48eb91d2813
dc.subjectcarbapenem derivativeen
dc.subjectcreatine kinaseen
dc.subjectdaptomycinen
dc.subjectglycopeptideen
dc.subjectpenicillin derivativeen
dc.subjectquinoline derived antiinfective agenten
dc.subjectantiinfective agenten
dc.subjectdaptomycinen
dc.subjectadulten
dc.subjectageden
dc.subjectantibiotic therapyen
dc.subjectArticleen
dc.subjectbactericidal activityen
dc.subjectbacterium isolateen
dc.subjectchilden
dc.subjectcoagulase negative Staphylococcusen
dc.subjectconcentration responseen
dc.subjectdebridementen
dc.subjectdevice infectionen
dc.subjectdrug efficacyen
dc.subjectdrug megadoseen
dc.subjectdrug safetyen
dc.subjectdrug treatment failureen
dc.subjectdrug withdrawalen
dc.subjectfemaleen
dc.subjecthumanen
dc.subjectmajor clinical studyen
dc.subjectmaleen
dc.subjectmethicillin resistant Staphylococcus aureusen
dc.subjectmethicillin susceptible Staphylococcus aureusen
dc.subjectmulticenter studyen
dc.subjectmyalgiaen
dc.subjectmyositisen
dc.subjectnonhumanen
dc.subjectorthopedic equipmenten
dc.subjectorthopedic prosthesisen
dc.subjectosteomyelitisen
dc.subjectpriority journalen
dc.subjectprosthesis infectionen
dc.subjectregisteren
dc.subjectretrospective studyen
dc.subjectrhabdomyolysisen
dc.subjectside effecten
dc.subjecttreatment outcomeen
dc.subjectadolescenten
dc.subjectbacteriumen
dc.subjectclassificationen
dc.subjectclinical trialen
dc.subjectEuropeen
dc.subjectisolation and purificationen
dc.subjectmicrobiologyen
dc.subjectmiddle ageden
dc.subjectosteomyelitisen
dc.subjectProsthesis-Related Infectionsen
dc.subjectvery elderlyen
dc.subjectyoung adulten
dc.subjectAdolescenten
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAnti-Bacterial Agentsen
dc.subjectBacteriaen
dc.subjectChilden
dc.subjectDaptomycinen
dc.subjectDebridementen
dc.subjectEuropeen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectOsteomyelitisen
dc.subjectProsthesis-Related Infectionsen
dc.subjectRetrospective Studiesen
dc.subjectTreatment Outcomeen
dc.subjectYoung Adulten
dc.subjectSpringer Verlagen
dc.titleDaptomycin for the treatment of osteomyelitis and orthopaedic device infections: real-world clinical experience from a European registryen
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής